Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2018 Feb;168(1):69-77.
doi: 10.1007/s10549-017-4550-8. Epub 2017 Nov 11.

21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology

Eleftherios P Mamounas  1   2 , Gong Tang  3 , Soonmyung Paik  4   5 , Frederick L Baehner  6 , Qing Liu  3 , Jong-Hyeon Jeong  3 , S Rim Kim  4 , Steven M Butler  6 , Farid Jamshidian  6 , Diana B Cherbavaz  6 , Amy P Sing  6 , Steven Shak  6 , Thomas B Julian  4   7 , Barry C Lembersky  4 , D Lawrence Wickerham  4   7 , Joseph P Costantino  3 , Norman Wolmark  4   7
Affiliations
Randomized Controlled Trial

21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology

Eleftherios P Mamounas et al. Breast Cancer Res Treat. 2018 Feb.

Abstract

Background: The 21-gene recurrence score (RS) predicts outcome and benefit from adjuvant chemotherapy benefit in breast cancer patients treated with adjuvant endocrine therapy. In the NSABP B-28 study, we evaluated the 21-gene RS for its prognostic impact and its ability to predict benefit from paclitaxel (P) in node-positive, estrogen receptor-positive (ER+) breast cancer patients treated with adjuvant chemotherapy plus tamoxifen.

Methods: The B-28 trial compared doxorubicin/cyclophosphamide (AC) with AC followed by P in 3060 patients. Tamoxifen for 5 years was also given to patients > 50 years and those < 50 years with ER+ and/or progesterone receptor-positive (PR+) tumors. The present study includes 1065 ER-positive, tamoxifen-treated patients with RS assessment. Median follow-up time was 11.2 years.

Results: In univariate analyses, RS was a significant predictor of outcome. In multivariate analyses, RS remained a significant independent predictor of outcome beyond clinico-pathologic factors, age, and type of surgery (p < 0.001). In the study population (n = 1065), the disease-free survival (DFS) hazard ratio (HR) with adding P to AC was 0.87 (95% CI 0.72-1.05; p = 0.14). RS was not a significant predictor of P benefit: for DFS, HRs for adding P to AC in RS low, intermediate, and high subgroups were 1.01 (95% CI 0.69-1.47; p = 0.99), 0.84 (95% CI 0.62-1.14; p = 0.26), and 0.81 (95% CI 0.60-1.10; p = 0.21), respectively (interaction p = 0.64). Similar findings were observed for the other study endpoints.

Conclusions: RS maintains significant prognostic impact in ER-positive, node-positive patients treated with adjuvant chemotherapy plus tamoxifen. However, RS did not significantly predict benefit from adding paclitaxel to AC chemotherapy. (Trial Registration: PDQ: NSABP-B-28).

Keywords: Breast cancer; Node-positive; Prognosis and prediction; Recurrence score.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Comparison of (A) disease-free survival (DFS) and (B) distant relapse-free interval (DRFI) between 1,065 ER-positive, B-28 patients who were included in the present study and 999 ER-positive, B-28 patients who were excluded.
Fig. 2
Fig. 2
Kaplan-Meier curves for (A) disease-free survival (DFS), (B) distant relapse-free interval (DRFI), (C) overall survival (OS), and (D) breast cancer-specific survival (BCSS) according to Recurrence Score categories: NSABP B-28
Fig. 3
Fig. 3
Kaplan-Meier curves for disease-free survival (DFS) according to Recurrence Score categories: NSABP B-28
Fig. 4
Fig. 4
Forest Plots of the effect of paclitaxel (P) according to Recurrence Score (RS) category: NSABP B-28
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. PNAS. 2001;98:10869–10874. - PMC - PubMed
    1. van de Vijver MJ, He YD, van ‘t Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347:1999–2009. - PubMed
    1. van ‘t Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415:530–536. - PubMed
    1. Foekens JA, Atkins D, Zhang Y, et al. Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. J Clin Oncol. 2006;24:1665–1671. - PubMed
    1. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351:2817–2826. - PubMed

Publication types

MeSH terms

Supplementary concepts